Combination therapy with amphotericin B and doxorubicin encapsulated in 
mannosylated nanomicelles for visceral leishmaniasis

Wei, Peng; Ye, Zhou; Cao, Shuya; Bai, Shuo; Seeberger, Peter H.; Yin, Jian; Hu, Jing

doi:10.1016/j.colsurfa.2020.124804

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Combination therapy with amphotericin B and doxorubicin encapsulated in mannosylated nanomicelles for visceral leishmaniasis

MPS-Authors

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Wei, P., Ye, Z., Cao, S., Bai, S., Seeberger, P. H., Yin, J., et al. (2020). Combination therapy with amphotericin B and doxorubicin encapsulated in mannosylated nanomicelles for visceral leishmaniasis. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 598: 124804. doi:10.1016/j.colsurfa.2020.124804.

Cite as: https://hdl.handle.net/21.11116/0000-0006-4D0A-A

Abstract

Drugs used to treat visceral leishmaniasis (VL) have severe side effects and face increasing resistance. We have created a mannose-functionalized nanomicelle carrying two drugs amphotericin B (AmB) and doxorubicin (DOX). The nanomicelles AmB&DOX@MCC preferentially target macrophages where Leishmania parasites reside and replicate, by the interaction between mannose residues on the micelle and mannose receptors (MRs) on the macrophage membrane. The combination of AmB and DOX leads to enhanced anti-leishmanial therapeutic efficacy through a synergistic effect. The mannose-fabricated nanomicelle is a promising formulation for leishmaniasis treatment.